Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1817 results
May 2017
-
Media ReleaseNovartis celebrates 21st annual Community Partnership Day with over 24,500 associates volunteering in their local communitiesCommunity Partnership Day symbolizes the company's commitment to improving people's lives and serving our local communities Follow the excitement with #NovartisCPD2017 and #proudmoments2017 via…
-
In The NewsNovartis Access perspective: The key to fighting chronic disease in South-East Asia - young peopleHarald Nusser, Head of Novartis Social Business, explains why educating young people is key to fighting chronic disease in South-East Asia.
-
Taking clinical trials to the next level through technology
Learn how Novartis is using technology to improve the oncology clinical trial process.
-
Media ReleaseNovartis exercises exclusive option agreement with Conatus for the treatment of NASHExclusive license for emricasan supports rapidly growing development portfolio in chronic liver diseases, including NASH Conatus has initiated the Phase IIb ENCORE-LF clinical trial with…
-
In The NewsNovartis Access perspective: How smart partnerships can help us fight chronic disease in AfricaHarald Nusser, Head of Novartis Social Business, talks about how the pharmaceutical industry can work with partners to overcome access issues in poor countries.
April 2017
-
Media ReleaseNovartis receives FDA approval for Rydapt® in newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of systemic mastocytosis (SM)Approval in newly diagnosed FLT3-mutated AML represents the first new treatment in more than 25 years[1],[2] Rydapt treatment regimen in FLT3-mutated AML demonstrated a significant improvement…
-
Media ReleaseAlcon announces EU launch of CyPass® Micro-Stent, a micro invasive glaucoma surgical device, to lower intraocular pressure (IOP) in patients with primary open-angle glaucomaNow available in the UK, Germany, Italy and Spain, CyPass Micro-Stent is designed to significantly reduce intraocular pressure (IOP) CE indication has been expanded to allow patients to be…
-
Media ReleaseNovartis delivered sales growth across all divisions (cc1) as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continuedNet sales grew 2% (cc, -1% USD), as growth drivers more than offset Gleevec/Glivec impact Cosentyx (USD 410 million, +136% cc) showing strong growth in all three indications Entresto (USD 84…
-
Media ReleaseNovartis: ventes en progression (tcc1) dans toutes ses divisions; les moteurs de croissance, Cosentyx et Entresto inclus, compensent l'érosion due aux génériques; l'innovation toujours en plein essorChiffre d'affaires net en hausse de 2% (tcc, -1% en USD), car les moteurs de croissance ont plus que compensé l'impact de Gleevec/Glivec Cosentyx (USD 410 millions, +136% tcc):…
-
Media ReleaseNovartis erzielt Umsatzsteigerungen in allen Divisionen (kWk1), wobei Wachstumstreiber wie Cosentyx und Entresto die Einbussen durch Generika mehr als wettmachen; Innovationsdynamik setzt sich fortDer Nettoumsatz wächst um 2% (kWk, -1% USD), da die Wachstumstreiber die Einbussen bei Glivec/Gleevec mehr als wettmachen Cosentyx (USD 410 Millionen, +136% kWk) erzielt in allen drei Indikationen…
-
Media ReleaseNovartis expands global collaboration with Amgen to commercialize first-in-class AMG 334 (erenumab) program in migraine prevention in the US and CanadaNovartis and Amgen to co-commercialize AMG 334 (erenumab) in the US; Novartis to gain exclusive rights in Canada Novartis retains commercial rights in rest of world; Amgen retains commercial…
-
Saving tumor suppressors from the shredder
Novartis opens up a path of research to protect proteins that guard against cancer.
Pagination
- ‹ Previous page
- 1
- …
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- …
- 152
- › Next page